A phase 1/2 study of IMT-009, an antibody targeting CD161, in patients with advanced solid tumors or lymphomas

In August 2021, LLS made an equity investment in Immunitas Therapeutics to support the "Phase 1 Clinical Development of IMT-009, an Antibody Targeting CD161, in Patients With Advanced Solid Tumors or Lymphomas." IMT-009, a first-in-class NK and T cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. Immunitas is also advancing IMT-073, a dual-target NK and T cell modulator. The company was founded by Longwood Fund with leading scientists from Dana-Farber, MGH, the Broad, and MIT.